Core Viewpoint - The company announced the approval of a plan to issue A-shares to specific investors during a board meeting scheduled for September 25, 2025, pending regulatory approvals [1] Group 1 - The company will hold a board and supervisory board meeting on September 25, 2025, to review the proposal for the issuance of A-shares [1] - The relevant proposal and announcement have been disclosed on the Giant Tide Information Network [1] - The issuance of shares is subject to approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1]

深圳翰宇药业股份有限公司第六届董事会 第二次独立董事专门会议审核意见 根据《中华人民共和国公司法》（以下简称《公司法》）《中华人民共和国 证券法》（以下简称《证券法》）《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相 关法律、法规及规范性文件的规定以及《公司章程》《独立董事工作细则》的有 关规定，我们作为公司的独立董事，基于独立判断的立场，本着实事求是的原则， 召开了第六届董事会第二次独立董事专门会议。 本次会议应出席独立董事 3 人，实际出席独立董事 3 人，独立董事认真审阅 了议案内容，在保证所获得的资料真实、准确、完整的基础上，本着勤勉尽责的 态度，基于独立客观的原则并发表审核意见如下： 一、《关于公司符合向特定对象发行 A 股股票条件的议案》的审核意见 经审核，我们认为：根据《公司法》《证券法》《上市公司证券发行注册管 理办法》（以下简称《注册管理办法》）等相关法律、法规及规范性文件的规定， 对照上市公司向特定对象发行股票（以下简称"本次发行"）相关资格、条件和 要求，经对公司的实际情况进行逐项自查，我们认为公司符合上述相关法律、法 ...

Group 1 - The cell immunotherapy sector experienced a decline of 2.75%, ranking among the top losers in the concept sector, with ST Zhongzhu hitting the daily limit down [1] - Major stocks within the cell immunotherapy sector that saw significant declines include Zhaoyan New Drug, Jimin Health, and Boteng Co., with respective drops of 6.04%, 5.45%, and 5.34% [1][2] - The sector faced a net outflow of 1.61 billion yuan from main funds, with 48 stocks experiencing outflows, and six stocks seeing outflows exceeding 100 million yuan, led by Hengrui Medicine with a net outflow of 293 million yuan [2] Group 2 - The top gainers in today's concept sectors included the SMIC concept with a rise of 1.22% and the National Big Fund holding with an increase of 1.08% [2] - The main inflows were observed in stocks such as Betta Pharmaceuticals, Chutian Technology, and Rongchang Bio, with net inflows of 35.97 million yuan, 21.30 million yuan, and 14.08 million yuan respectively [4] - The overall market sentiment reflected a mixed performance across various sectors, with notable declines in the Huawei Pangu and MLOps concepts, down 3.69% and 3.31% respectively [2]

Group 1 - On September 19, Hanyu Pharmaceutical experienced a decline of 2.74% with a trading volume of 1.232 billion yuan [1] - The financing data on the same day showed a financing purchase amount of 120 million yuan and a financing repayment of 159 million yuan, resulting in a net financing outflow of 38.83 million yuan [1] - As of September 19, the total balance of margin trading for Hanyu Pharmaceutical was 1.473 billion yuan, accounting for 6.91% of its circulating market value, which is above the 80th percentile of the past year [1] Group 2 - As of June 30, the number of shareholders for Hanyu Pharmaceutical reached 63,000, an increase of 9.95% compared to the previous period [2] - The company reported a revenue of 549 million yuan for the first half of 2025, representing a year-on-year growth of 114.86%, and a net profit attributable to shareholders of 145 million yuan, a significant increase of 1504.30% [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends paid in the last three years [2]

公司指出，该大模型工艺优化助手已在多个研发和生产环节展现出了突破性成效，这些成果不仅验证了 大模型技术在医药研发领域的巨大应用价值，也凸显了翰宇药业在多肽数智化转型中的先发优势。进一 步体现在量化数据上，该大模型的应用将实现研发周期缩短45%、试错成本降低20%以上、工艺参数决 策效率提升90%、批次合格率提升22%。 值得一提的是，翰宇药业与华为云的合作，很好地契合了近年来国家政策的导向。今年4月24日由工信 部等七部门联合发布的《医药工业数智化转型实施方案（2025-2030年）》就指出，到2030年规模以上 医药工业企业要基本实现数智化转型全面覆盖，数智技术与医药产业的融合创新能力需实现质的飞跃。 至8月26日，国务院发布的《关于深入实施"人工智能+"行动的意见》，更明确提出了"有序推动人工智 能在辅助诊疗、健康管理、医保服务等场景的应用"，旨在通过AI赋能医疗健康领域，加快培育发展新 质生产力，更好地服务中国式现代化建设。 9月18日至20日，第十届华为全联接大会（HUAWEI CONNECT 2025）在上海举行。其中，医药领域分 论坛"AI+医药构筑新质生产力"汇聚行业精英，共同探讨医药行业未来发 ...

9月9日，翰宇药业跌1.68%，成交额14.06亿元。两融数据显示，当日翰宇药业获融资买入额1.13亿元， 融资偿还1.16亿元，融资净买入-289.27万元。截至9月9日，翰宇药业融资融券余额合计15.19亿元。 融资方面，翰宇药业当日融资买入1.13亿元。当前融资余额15.19亿元，占流通市值的7.16%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，翰宇药业9月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年70%分位水平，处于较高位。 资料显示，深圳翰宇药业股份有限公司位于广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产 业大楼，成立日期2003年4月2日，上市日期2011年4月7日，公司主营业务涉及化学制药和医疗器械。主 营业务收入构成为：医药制造业100.00%。 截至6月30日，翰宇药业股东户数6.30万，较上期增加9.95%；人均流通股11841股，较上期减少3.98%。 2025年1月-6月，翰宇药业实现营业收入5.49亿元，同比增长114.86%；归母净利润1.45亿元，同比增长 1504 ...

Company Overview - Hanyu Pharmaceutical Co., Ltd. is located in Longhua District, Shenzhen, Guangdong Province, and was established on April 2, 2003. The company was listed on April 7, 2011. Its main business involves chemical pharmaceuticals and medical devices, with 100% of its revenue coming from the pharmaceutical manufacturing industry [1]. Stock Performance - As of September 3, Hanyu Pharmaceutical's stock price decreased by 2.02%, trading at 26.16 CNY per share, with a total market capitalization of 23.106 billion CNY. The stock has increased by 102.95% year-to-date, with a 0.19% increase over the last five trading days, an 11.79% increase over the last 20 days, and a 53.88% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on August 4, where it recorded a net purchase of 545 million CNY [1]. Financial Performance - For the first half of 2025, Hanyu Pharmaceutical achieved a revenue of 549 million CNY, representing a year-on-year growth of 114.86%. The net profit attributable to the parent company was 145 million CNY, showing a significant year-on-year increase of 1504.30% [2]. - The company has distributed a total of 417 million CNY in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 9.95% to 63,000, with an average of 11,841 circulating shares per person, a decrease of 3.98% from the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.6817 million shares, which is a decrease of 386,400 shares compared to the previous period [3].

Core Viewpoint - The pharmaceutical industry, particularly biotech companies, is expected to experience a significant market upturn from late 2024 to mid-2025, supported by global market growth and strong performance in the Chinese pharmaceutical market [1][3]. Market Trends - The rapid growth of BD (business development) activities, the reopening of the Sci-Tech Innovation Board, and the performance of Hong Kong's secondary market indicate that the industry is entering a valuation recovery phase [1]. - Despite some biotech companies experiencing substantial stock price increases, many investors have not yet recouped their costs due to the timing of investments [1][2]. Investment Landscape - High-quality companies that address clinical needs are more likely to survive market downturns, while many biotech firms have failed to navigate the recent market challenges [2]. - The current secondary market appears prosperous, but from the perspective of primary market entrepreneurs, it is still in a winter phase [2]. Challenges and Opportunities - The difficulty of listing biotech companies in both China and the U.S. has led to diversified financing channels, with investors focusing on asset quality and clinical research data [3]. - The demand for high-quality, cost-effective products is increasing due to global aging populations and limited healthcare funding [4]. Global Positioning - Chinese innovators have significantly narrowed the development gap with the U.S., with a reported 38% year-on-year increase in overseas licensing deals, totaling $60.8 billion in the first half of 2025 [5][6]. - The shift from generic to original drug development in China is expected to have a profound impact on the global pharmaceutical market [6]. R&D Efficiency - China leads globally in R&D efficiency from "1 to 10," while the U.S. remains dominant in "0 to 1" development [6]. - The ability to produce unique products, particularly in ADC (antibody-drug conjugates), is attributed to China's strong engineering capabilities [9]. Future Growth Areas - The most promising research areas for capital investment are in immunology and metabolic/cardiovascular fields [7]. - The market is witnessing a divide, with leading companies leveraging innovation and digital empowerment, while smaller firms face greater pressure due to homogenized competition [6][10]. Strategic Directions - Companies are encouraged to explore new financing models, such as RWA (Real World Asset) tokenization, to better access markets [11]. - The focus on license-out opportunities and the promotion of inclusive healthcare are critical strategies for pharmaceutical companies [12].

Group 1 - The weight loss drug concept sector increased by 1.80%, ranking 6th among concept sectors, with 33 stocks rising, including Puris with a 20% limit up, and Haoyuan Pharmaceutical, Medisi, and Xinnowei with increases of 13.70%, 8.96%, and 7.30% respectively [1][2] - The leading stocks in terms of net inflow of main funds in the weight loss drug sector included Heng Rui Pharmaceutical with a net inflow of 5.35 billion yuan, followed by Hanyu Pharmaceutical, Fosun Pharmaceutical, and Kailai Ying with net inflows of 819.35 million yuan, 618.34 million yuan, and 589.18 million yuan respectively [2][3] Group 2 - The main fund inflow ratios for stocks in the weight loss drug sector were led by Puris at 21.03%, followed by Nawei Technology at 11.85% and Sunshine Nuohe at 8.90% [3][4] - The stocks with significant daily trading volume and net inflow ratios included Heng Rui Pharmaceutical with a daily increase of 5.08% and a turnover rate of 1.60%, and Hanyu Pharmaceutical with a daily increase of 3.34% and a turnover rate of 13.37% [3][4] Group 3 - The weight loss drug sector saw a total net inflow of 5.52 billion yuan, with 27 stocks experiencing net inflows, and 6 stocks receiving over 500 million yuan in net inflows [2][3] - The stocks that experienced the largest declines included Dezhan Health, *ST Sansheng, and Borui Pharmaceutical, with decreases of 1.81%, 1.74%, and 1.60% respectively [1][6]

Market Overview - The Shanghai Composite Index rose by 1.14% on August 28, with 22 out of 28 sectors experiencing gains, led by the communication and electronics sectors, which increased by 7.14% and 5.53% respectively [1] - Conversely, the coal and agriculture sectors saw declines of 0.81% and 0.73% respectively, while the pharmaceutical and biotechnology sector fell by 0.20% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 44.343 billion yuan, with five sectors experiencing net inflows. The electronics sector led with a net inflow of 10.553 billion yuan, followed by the communication sector with 4.998 billion yuan [1] - In contrast, 26 sectors faced net capital outflows, with the computer sector experiencing the largest outflow of 11.007 billion yuan, followed by the pharmaceutical and biotechnology sector with an outflow of 7.892 billion yuan [1] Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector had a net outflow of 7.892 billion yuan, with 474 stocks in the sector. Out of these, 121 stocks rose, including 2 that hit the daily limit, while 346 stocks declined [2] - Notably, the top three stocks with the highest net inflow were Tibet Pharmaceutical with 320 million yuan, followed by Furuide with 293 million yuan, and Jimin Health with 126 million yuan [2] - The sector's outflow was dominated by WuXi AppTec, which saw a net outflow of 596 million yuan, followed by Borui Pharmaceutical and Hanyu Pharmaceutical with outflows of 548 million yuan and 339 million yuan respectively [3]